{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:38:48Z","timestamp":1771875528236,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the drug retention times and clinical efficacy of alternative tumour necrosis factor inhibitors (TNFi) and secukinumab in primary and secondary non-responders with ankylosing spondylitis (AS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>AS patients treated with biologics and enrolled in the Korean College of Rheumatology Biologics registry were examined. Patients who did not respond to previous TNFi treatment were defined as primary and secondary non-responders. Data regarding drug discontinuation and clinical efficacy were collected after 1\u2009year. Kaplan\u2013Meier and Cox regression analyses were performed to compare drug survival and associated factors. Logistic regression analyses were conducted to compare the clinical efficacy secukinumab with that of alternative TNFi.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 124 patients (83 receiving alternative TNFi and 41 receiving secukinumab) had biologic changes due to clinical inefficacy. Drug retention rates in the alternative TNFi and secukinumab groups were similar (P\u2009=\u20090.096). However, subgroup analyses including only secondary non-responders revealed that secukinumab users showed a higher hazard ratio (HR) for drug discontinuation (HR\u2009=\u20093.77, P\u2009=\u20090.045). In addition, secukinumab was negatively associated with achieving BASDAI50 or a major improvement in the ASDAS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Alternative TNFi showed better drug retention and clinical efficacy in AS patients experiencing previous TNFi failure, in secondary non-responders. Therefore, alternative TNFi may be a more suitable treatment for secondary non-responders.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac005","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T12:58:11Z","timestamp":1643806691000},"page":"194-201","source":"Crossref","is-referenced-by-count":9,"title":["Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-1046","authenticated-orcid":false,"given":"Hong Ki","family":"Min","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Konkuk University Medical Center , 120-1 Neungdong-ro, Gwangjin-gu, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae-Rim","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Research Institute of Medical Science, Konkuk University Medical Center, Konkuk University School of Medicine , 120-1 Neungdong-ro, Gwangjin-gu, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Heon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Research Institute of Medical Science, Konkuk University Medical Center, Konkuk University School of Medicine , 120-1 Neungdong-ro, Gwangjin-gu, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Sik","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, College of Medicine, The Catholic University of Korea , Seoul, South Korea"},{"name":"Department of Internal Medicine, Division of Rheumatology, Incheon Saint Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , Incheon, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Incheon Saint Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , Incheon, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, College of Medicine, The Catholic University of Korea , Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0059-119X","authenticated-orcid":false,"given":"Kwi Young","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, College of Medicine, The Catholic University of Korea , Seoul, South Korea"},{"name":"Department of Internal Medicine, Division of Rheumatology, Incheon Saint Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea , Incheon, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"2023011210563972600_R1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2023011210563972600_R3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MAJ.0b013e3182514093","article-title":"Economic considerations of the treatment of ankylosing spondylitis","volume":"343","author":"Reveille","year":"2012","journal-title":"Am J Med Sci"},{"key":"2023011210563972600_R4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"2023011210563972600_R5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2023011210563972600_R6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R7","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023011210563972600_R8","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023011210563972600_R9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R10","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"2023011210563972600_R11","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet (London, England)"},{"key":"2023011210563972600_R12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2023011210563972600_R13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4078\/jrd.2017.24.5.287","article-title":"Comparison of the disease activity score-28 based on the erythrocyte sedimentation rate and C-reactive protein in rheumatoid arthritis","volume":"24","author":"Choi","year":"2017","journal-title":"J Rheum Dis"},{"key":"2023011210563972600_R14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2023011210563972600_R15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care & Research"},{"key":"2023011210563972600_R16","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1032-6","article-title":"The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011-2015","volume":"14","author":"Lim","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2023011210563972600_R17","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2023011210563972600_R18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R19","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2023011210563972600_R20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","article-title":"Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort","volume":"79","author":"Micheroli","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R21","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1007\/s10067-018-4290-0","article-title":"The effect of extra-articular manifestations on tumor necrosis factor-\u03b1 inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry","volume":"37","author":"Kim","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023011210563972600_R22","article-title":"Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort","volume":"22","author":"Ciurea","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023011210563972600_R23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","article-title":"Review: the interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2023011210563972600_R24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2019-216741","article-title":"Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence","volume":"79","author":"Koo","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R26","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab245","article-title":"Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure","volume":"60","author":"Min","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2023011210563972600_R27","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02288-8","article-title":"Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?","volume":"22","author":"Manica","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023011210563972600_R28","article-title":"One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in Spondyloarthritis","author":"Glintborg","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"2023011210563972600_R29","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011210563972600_R30","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.37920","article-title":"Neuropathic pain in ankylosing spondylitis: a psychophysics and brain imaging study","volume":"65","author":"Wu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023011210563972600_R31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00296-007-0344-3","article-title":"Fibromyalgia in women with ankylosing spondylitis","volume":"27","author":"Aloush","year":"2007","journal-title":"Rheumatol Int"},{"key":"2023011210563972600_R32","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1093\/rheumatology\/keaa527","article-title":"Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis","volume":"59","author":"Ortolan","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"2023011210563972600_R33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/keh483","article-title":"Anti-TNF-alpha therapies: they are all the same (aren\u2019t they?)","volume":"44","author":"Mpofu","year":"2005","journal-title":"Rheumatology (Oxford, England)"},{"key":"2023011210563972600_R34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3899\/jrheum.170224","article-title":"Comparative efficacy of tumor necrosis factor-\u03b1 inhibitors in ankylosing spondylitis: a systematic review and Bayesian network metaanalysis","volume":"45","author":"Wang","year":"2018","journal-title":"J Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac005\/43406255\/roac005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/194\/48626440\/roac005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/194\/48626440\/roac005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:03:42Z","timestamp":1673525022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/1\/194\/6520264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,2]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac005","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,2,2]]}}}